Oral Ciprofloxacin Prophylaxis in Patients Undergoing High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation

Authors

  • Abbas Hajifathali Taleghani Bone Marrow Transplantation Center, Taleghani Hospital, Shahid Beheshti University Of Medical Sciences, Evin, Tehran, Iran.
  • Hmid Rezvani Hematology And Oncology Center, Taleghani hospital, Shahid Beheshti University Of Medical Sciences, Tehran, Iran
  • Mahdi Tabarraee Hematology And Oncology Center, Taleghani hospital, Shahid Beheshti University Of Medical Sciences, Tehran, Iran
  • Mahshid Mehdizadeh Taleghani Bone Marrow Transplantation Center, Taleghani Hospital, Shahid Beheshti University Of Medical Sciences, Evin, Tehran, Iran.
  • Mojtaba Ghadiany Hematology And Oncology Center, Taleghani hospital, Shahid Beheshti University Of Medical Sciences, Tehran, Iran
  • samiyeh Khamsi Hematology And Oncology Center, Taleghani hospital, Shahid Beheshti University Of Medical Sciences, Tehran, Iran
Abstract:

Background: Antibiotic prophylaxis is usually used in allogenic stem cell transplantation, but its use in Autologous Stem Cell Transplantation (ASCT) is controversial. We evaluated the efficacy of ciprofloxacin prophylaxis in ASCT. Materials and Methods: To identify the efficacy of ciprofloxacin on the incidence of neutropenic fever and its complications, 72 patients had been admitted to Taleghani Hospital for ASCT between 2010 and 2012 were evaluated in our study. Oral ciprofloxacin 500 mg BID was administered to 30 patients on the same day of high dose chemotherapy until the first febrile episode or until the recovery of neutropenia and the results were analyzed and compared with the historical control group 42 other transplanted patients who had not previously received ciprofloxacin. Results: The incidence of neutropenic fever was 80% with no difference between the two groups. But in ciprofloxacin group, duration of fever (1.7 days VS 3.5 days P=0.017), hospitalization deu to stem cell transfusion (18.2 days VS 12.2 days p=0.03), incidence of bacteremia 3.3 % VS 33.3%, p=0.002) and platelet recovery (13.9 VS 17.7 days= 0.035) and platelet transfusions (P=0.04) were significantly lower than the control group no side effects and no delay in. Conclusion: Based on this study oral ciprofloxacin prophylaxis is rational, efficacious and economic in ASCT.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

oral ciprofloxacin prophylaxis in patients undergoing high dose therapy and autologous hematopoietic stem cell transplantation

background: antibiotic prophylaxis is usually used in allogenic stem cell transplantation, but its use in autologous stem cell transplantation (asct) is controversial. we evaluated the efficacy of ciprofloxacin prophylaxis in asct. materials and methods: to identify the efficacy of ciprofloxacin on the incidence of neutropenic fever and its complications, 72 patients had been admitted to talegh...

full text

Oral Ciprofloxacin Prophylaxis in Patients Undergoing High DoseTherapy and Autologous Hematopoietic Stem Cell Transplantation

Antibiotic prophylaxis is usually used in allogeneic stem cell transplantation, but its use in Autologous Stem Cell Transplantation (ASCT) is controversial. We evaluated the efficacy of ciprofloxacin prophylaxis in ASCT. To identify the efficacy of ciprofloxacin on the incidence of neutropenic fever and its complications, 72 patients that had been admitted to Taleghani Hospital for ASCT between...

full text

Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation

BACKGROUND AND THE PURPOSE OF THE STUDY Many factors have been reported that contribute to the wide intra- and inter-patient variability of Busulfan (Bu) disposition. The purpose of this study was to develop a population pharmacokinetic model and to determine the covariates affecting the pharmacokinetics (PK) of Bu in Iranian adult patients who received oral high-dose as a conditioning regimen ...

full text

Pediatric Hematopoietic Stem Cell Transplantation

The introduction and evolution of hematopoietic stem cell transplantation (HSCT) could be traced back to 1950s, to the studies on interactions among irradiation, covering spleen and bone marrow from it and injection of bone marrow cells. Today, HSCT is considered a well-established, effective and promising means of therapy for various malignant and non-malignant medical conditions, both in chil...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 15  issue Special Issue

pages  159- 163

publication date 2016-03-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023